A sub-analysis of phase 2 data compared the immunogenicity of their VLA15 vaccine in adults after administration of 2 or 3 primary series doses with the latter demonstrating a stronger response.
About 300,000 people get Lyme disease each year. A new investigational prophylactic could provide people in high-risk settings with an opportunity to prevent infection.